AquaNabs produces organic nano‑antibody treatments derived from alpaca immunisation to combat pathogens such as sea lice in salmon farming. The non‑toxic, residue‑free solution integrates quickly on‑site, improving fish health and performance while reducing environmental impact. By leveraging protein‑based nano‑antibodies, AquaNabs offers a sustainable, precision‑care approach for aquaculture operations seeking effective, low‑stress disease control.
Funding
Funding not disclosed
Founders
Product
Problem
Sea lice infestations cause significant health issues and reduced growth in salmon farms, leading to economic losses and increased reliance on chemical treatments that can be toxic and leave residues.
Solution
AquaNabs offers a biologically based treatment that uses nanoantibodies derived from alpaca immunization to target sea lice parasites. The nanoantibody formulation is non‑toxic, residue‑free, and designed for rapid on‑site integration, minimizing operational complexity for fish farms. By specifically binding to lice antigens, the product reduces parasite load while supporting overall fish health and performance. The solution is produced from 100 % organic protein sources, providing a sustainable alternative that lowers the environmental footprint of salmon aquaculture.
Target Audience
Primary customers are commercial salmon farms and aquaculture operations seeking effective, sustainable parasite control solutions.
Features
- Nanoantibody technology generated from alpaca immunization for high specificity against sea lice
- Non‑toxic, residue‑free formulation that eliminates concerns about chemical contamination
- Rapid on‑site integration with minimal equipment or procedural changes required
- Organic protein‑based production process that reduces environmental impact
- Designed to lower the risk of parasite resistance through targeted biological action